港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

宜明昂科-B

7.020

+0.64010.03%

成交量：497.82萬

成交額：3,425.85萬

市值：28.57億

市盈率：-7.74

高：7.240

開：6.400

低：6.330

收：6.380

資料載入中...

總覽公司新聞資訊公告

宜明昂科-B盤中異動早盤大幅下挫5.81%報4.860港元

宜明昂科-B盤中異動早盤股價大漲5.30%

宜明昂科-B01月23日主力資金流出31萬元連續3日減倉

宜明昂科-B盤中異動股價大漲5.10%報5.150港元

宜明昂科－Ｂ(01541)股價上升5.102%，現價港幣$5.15

阿斯达克财经

港股異動 | 宜明昂科-B(01541)現漲近6% IMM2510聯合化療臨牀試驗完成首例患者給藥

宜明昂科-B盤中異動早盤急速拉昇5.17%報4.880港元

宜明昂科-B高開逾3% IMM2510聯合化療臨牀試驗完成首例患者給藥

異動解讀 | 宜明昂科-B肺癌新藥臨牀試驗取得進展,股價大漲5.43%

港股異動 | 宜明昂科-B(01541)高開逾3% IMM2510聯合化療臨牀試驗完成首例患者給藥

宜明昂科(01541.HK)IMM2510聯合化療臨牀試驗完成首例患者給藥

阿斯达克财经

宜明昂科完成IMM2510首例患者給藥

宜明昂科-B(01541)：IMM2510聯合化療進行NSCLC一線治療的IB/II期臨牀試驗完成首例患者給藥

宜明昂科-B盤中異動股價大跌5.33%

宜明昂科擬出售附屬公司資產評估值為1.01億元

宜明昂科-B(01541)下跌5.42%，報4.89元/股

宜明昂科-B盤中異動下午盤急速跳水5.42%

港股異動 | 宜明昂科-B(01541)盤中漲超5% 近期出售土地及配股籌集資金 CD47/SIRPα融合蛋白進入III期臨牀

宜明昂科-B盤中異動大幅上漲5.18%報5.280港元

宜明昂科-B(01541)上漲5.07%，報5.39元/股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01541/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01541","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":7.02,"timestamp":1747210103029,"preClose":6.38,"halted":0,"volume":4978200,"delay":0,"floatShares":382000000,"shares":407000000,"eps":-0.9065372521567371,"marketStatus":"未開盤","change":0.64,"latestTime":"05-14 16:08:23","open":6.4,"high":7.24,"low":6.33,"amount":34258482,"amplitude":0.142633,"askPrice":7.08,"askSize":5000,"bidPrice":7.02,"bidSize":40000,"shortable":3,"etf":0,"ttmEps":-0.9065372521567371,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1747272600000},"marketStatusCode":0,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":6.38,"openAndCloseTimeList":[[1747186200000,1747195200000],[1747198800000,1747209600000]],"volumeRatio":1.758932,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","floatShares":382000000,"roa":"-21.43%","roe":"-44.38%","lyrEps":-0.906537,"volumeRatio":1.758932,"shares":407000000,"dividePrice":0,"high":7.24,"amplitude":0.142633,"preClose":6.38,"low":6.33,"week52Low":3.21,"pbRate":"3.89","psRate":"33.19","week52High":22,"institutionHeld":0,"latestPrice":7.02,"committee":0.777778,"eps":-0.9065372521567371,"divideRate":0,"volume":4978200,"delay":0,"ttmEps":-0.9065372521567371,"open":6.4,"prevYearClose":5.16,"prevWeekClose":6.44,"prevMonthClose":6.25,"prevQuarterClose":5.84,"fiveDayClose":6.04,"twentyDayClose":4.95,"sixtyDayClose":5.63},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01541\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508353163","title":"宜明昂科-B盤中異動 早盤大幅下挫5.81%報4.860港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508353163","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508353163?lang=zh_tw&edition=fundamental","pubTime":"2025-02-03 09:37","pubTimestamp":1738546633,"startTime":"0","endTime":"0","summary":"2025年02月03日早盘09时37分，宜明昂科-B股票出现异动，股价急速下跌5.81%。截至发稿，该股报4.860港元/股，成交量4.74万股，换手率0.01%，振幅5.23%。资金方面，该股资金流入0港元，流出23.0976万港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为1.52%。其相关个股中，百奥赛图-B、亚盛医药-B、和铂医药-B涨幅较大，振幅较大的相关个股有泰格医药、基石药业-B、宜明昂科-B，振幅分别为7.66%、7.26%、5.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203093713abc06d9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203093713abc06d9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2505074747","title":"宜明昂科-B盤中異動 早盤股價大漲5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505074747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505074747?lang=zh_tw&edition=fundamental","pubTime":"2025-01-24 09:30","pubTimestamp":1737682207,"startTime":"0","endTime":"0","summary":"2025年01月24日早盘09时30分，宜明昂科-B股票出现波动，股价大幅上涨5.30%。截至发稿，该股报5.170港元/股，成交量8.18万股，换手率0.02%，振幅2.24%。资金方面，该股资金流入5.9816万港元，流出4048港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，宜明昂科-B、泰格医药、乐普生物-B涨幅较大，振幅较大的相关个股有泰格医药、亚盛医药-B、宜明昂科-B，振幅分别为3.20%、2.40%、2.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012409300798713d4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012409300798713d4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2505706329","title":"宜明昂科-B01月23日主力資金流出31萬元 連續3日減倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706329","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706329?lang=zh_tw&edition=fundamental","pubTime":"2025-01-23 16:15","pubTimestamp":1737620149,"startTime":"0","endTime":"0","summary":"01月23日, 宜明昂科-B股价跌2.39%，报收4.91元，成交金额2095万元，换手率1.09%，振幅6.36%，量比0.76。宜明昂科-B今日主力资金净流出31万元，连续3日净流出，上一交易日主力净流出52万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为60.00%，平均跌幅为4.42%。该股近5个交易日上涨1.44%，主力资金累计净流出112万元；近20日主力资金累计净流出25万元，其中净流出天数为10日。该股主力净额占比0.02%，港股市场排名2492/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123161608a22ca420&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123161608a22ca420&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2504429047","title":"宜明昂科-B盤中異動 股價大漲5.10%報5.150港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504429047","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504429047?lang=zh_tw&edition=fundamental","pubTime":"2025-01-20 09:40","pubTimestamp":1737337244,"startTime":"0","endTime":"0","summary":"2025年01月20日早盘09时40分，宜明昂科-B股票出现异动，股价大幅上涨5.10%。截至发稿，该股报5.150港元/股，成交量49.96万股，换手率0.13%，振幅4.08%。资金方面，该股资金流入148.772万港元，流出51.0262万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。宜明昂科-B股票所在的生物技术行业中，整体涨幅为0.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120094044986c1bc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120094044986c1bc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2504074410","title":"宜明昂科－Ｂ(01541)股價上升5.102%，現價港幣$5.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2504074410","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504074410?lang=zh_tw&edition=fundamental","pubTime":"2025-01-20 09:40","pubTimestamp":1737337200,"startTime":"0","endTime":"0","summary":"[上升股]宜明昂科－Ｂ(01541) 股价在上午09:40比前收市价上升5.102%，现股价为港币$5.15。至目前为止，今日最高价为$5.15，而最低价为$4.95。总成交量为47.78万股，总成交金额为港币$241.804万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2501201223/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2503516981","title":"港股異動 | 宜明昂科-B(01541)現漲近6% IMM2510聯合化療臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2503516981","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503516981?lang=zh_tw&edition=fundamental","pubTime":"2025-01-16 10:25","pubTimestamp":1736994314,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B现涨近6%，截至发稿，涨4.09%，报4.83港元，成交额1372.29万港元。消息面上，宜明昂科公告，IMM2510联合化疗进行非小细胞肺癌一线治疗的Ib/II期临床试验成功完成首例患者给药。此外，宜明昂科近期完成配售事宜，净筹约2.3亿港元，其中70%用于在中国进行包括替达派西普与替雷利珠单抗联合疗法的关键性临床研究提供资金；及约30%作一般企业用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1238451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","01541","03347","BK1161"],"gpt_icon":0},{"id":"2503931706","title":"宜明昂科-B盤中異動 早盤急速拉昇5.17%報4.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503931706","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503931706?lang=zh_tw&edition=fundamental","pubTime":"2025-01-16 09:49","pubTimestamp":1736992191,"startTime":"0","endTime":"0","summary":"2025年01月16日早盘09时49分，宜明昂科-B股票出现波动，股价急速上涨5.17%。截至发稿，该股报4.880港元/股，成交量114.9万股，换手率0.30%，振幅4.74%。资金方面，该股资金流入184.565万港元，流出221.247万港元。宜明昂科-B股票所在的生物技术行业中，整体涨幅为1.45%。其相关个股中，北海康成-B、宜明昂科-B、晶泰控股-P涨幅较大，振幅较大的相关个股有北海康成-B、巨子生物、华康生物医学，振幅分别为22.12%、4.87%、4.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501160949529867d324&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501160949529867d324&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2503561108","title":"宜明昂科-B高開逾3% IMM2510聯合化療臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2503561108","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503561108?lang=zh_tw&edition=fundamental","pubTime":"2025-01-14 09:33","pubTimestamp":1736818380,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　宜明昂科-B（01541）早盘高开，截至发稿，股价上涨3.48%，现报4.76港元，成交额385.48万港元。\n　　宜明昂科-B发布公告，IMM2510联合化疗进行非小细胞肺癌（NSCLC）一线治疗的Ib/II期临床试验成功完成首例患者给药。安全性导入期后，公司计划在上述临床试验中招募一线患者，预计最早于2025年下半年发布初步临床数据，包括来自NSCLC一线患者的数据。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-01-14/doc-ineewwwe2155190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03347","BK1576","BK1161","BK1583","01541","BK1141"],"gpt_icon":0},{"id":"1199213320","title":"異動解讀 | 宜明昂科-B肺癌新藥臨牀試驗取得進展,股價大漲5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199213320","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199213320?lang=zh_tw&edition=fundamental","pubTime":"2025-01-14 09:32","pubTimestamp":1736818350,"startTime":"0","endTime":"0","summary":"宜明昂科-B(01541.HK)今日盘中大涨5.43%,股价异动引起市场广泛关注。\n\n据相关披露,公司自主研发的一种联合化疗方案IMM2510,旨在用于非小细胞肺癌(NSCLC)一线治疗,已完成了Ib/II期临床试验首例患者的给药。在完成安全性导入期后,公司将在上述临床中招募更多一线患者,并计划在2025年下半年发布初步临床数据。\n\n这一进展表明宜明昂科在研发创新药物、为肺癌患者提供新的治疗方案方面取得了重要进展,未来有望推出具有疗效的肺癌新药。由于临床前景向好,投资者对公司发展前景抱有信心,因此推动了今日股价大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 宜明昂科-B肺癌新药临床试验取得进展,股价大涨5.43%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"2503256137","title":"港股異動 | 宜明昂科-B(01541)高開逾3% IMM2510聯合化療臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2503256137","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503256137?lang=zh_tw&edition=fundamental","pubTime":"2025-01-14 09:29","pubTimestamp":1736818166,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B高开逾3%，截至发稿，涨3.7%，报4.77港元，成交额38.73万港元。消息面上，宜明昂科-B发布公告，IMM2510联合化疗进行非小细胞肺癌一线治疗的Ib/II期临床试验成功完成首例患者给药。安全性导入期后，公司计划在上述临床试验中招募一线患者，预计最早于2025年下半年发布初步临床数据，包括来自NSCLC一线患者的数据。截至2024年12月31日，招募超过100名患者加入IMM2510单药治疗的I/II期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1237158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","01541","03347","BK1161"],"gpt_icon":0},{"id":"2503077589","title":"宜明昂科(01541.HK)IMM2510聯合化療臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2503077589","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503077589?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 23:21","pubTimestamp":1736781660,"startTime":"0","endTime":"0","summary":"宜明昂科－Ｂ(01541.HK) 公布，集团自主研发的IMM2510联合化疗进行非小细胞肺癌(NSCLC)一线治疗的Ib/II期临床试验成功完成首例患者给药。安全性导入期后，公司计划在上述临床试验中招募一线患者，预计最早于2025年下半年发布初步临床数据。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410008/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1576","BK1141","BK1583","01541","03347"],"gpt_icon":0},{"id":"2503064753","title":"宜明昂科完成IMM2510首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2503064753","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503064753?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 20:51","pubTimestamp":1736772677,"startTime":"0","endTime":"0","summary":"财中社1月13日电宜明昂科-B（01541）发布公告，宣布IMM2510联合化疗进行非小细胞肺癌（NSCLC）一线治疗的Ib/II期临床试验成功完成首例患者给药。公司计划在安全性导入期后招募一线患者，并预计最早于2025年下半年发布初步临床数据。根据IMM2510I期剂量递增研究的临床数据，部分接受过多种疗法失败的晚期实体瘤患者在接受IMM2510治疗后达到了部分缓解（PR）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501133295451735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01541","BK1161","BK4213","PR"],"gpt_icon":0},{"id":"2503430669","title":"宜明昂科-B(01541)：IMM2510聯合化療進行NSCLC一線治療的IB/II期臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2503430669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503430669?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 20:35","pubTimestamp":1736771730,"startTime":"0","endTime":"0","summary":"截至2024年12月31日，招募超过100名患者加入IMM2510单药治疗的I/II期临床试验。IMM2510的Ib/II期临床研究目前正积极推进，涵盖多种实体瘤适应症，包括单药治疗及与多种治疗方式联合使用。于2023年11月，本公司成功对IMM2510单药治疗晚期或复发难治性(R/R)实体瘤的II期临床试验完成首例患者给药。于2024年12月27日，本公司成功对IMM2510联合化疗进行NSCLC一线治疗的Ib期临床试验完成首例患者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1237026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1576","BK1583","BK1141","03347","BK1161"],"gpt_icon":0},{"id":"2503312528","title":"宜明昂科-B盤中異動 股價大跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503312528","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503312528?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 09:34","pubTimestamp":1736732044,"startTime":"0","endTime":"0","summary":"2025年01月13日早盘09时34分，宜明昂科-B股票出现异动，股价急速跳水5.33%。截至发稿，该股报4.620港元/股，成交量81.06万股，换手率0.21%，振幅6.15%。资金方面，该股资金流入16.763万港元，流出206.943万港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为0.45%。宜明昂科-B公司简介：宜明昂科生物医药技术(上海)股份有限公司是一家主要从事测试生物技术研发的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113093404a21f772a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113093404a21f772a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2502855487","title":"宜明昂科擬出售附屬公司 資產評估值為1.01億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502855487","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502855487?lang=zh_tw&edition=fundamental","pubTime":"2025-01-10 18:38","pubTimestamp":1736505537,"startTime":"0","endTime":"0","summary":"财中社1月10日电宜明昂科-B（01541）发布公告，提供有关出售附属公司的交易信息。根据2024年12月30日的公告，目标公司的资产总额评估值为1.01亿元，主要包括位于上海浦东新区的工业土地。估值是由上海财瑞资产评估有限公司于2024年11月6日完成，采用了资产法进行评估。公告中提到，目标公司的负债总额为9790万元，资产与负债的差额决定了股权的评估值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501103293864224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2502885671","title":"宜明昂科-B(01541)下跌5.42%，報4.89元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2502885671","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502885671?lang=zh_tw&edition=fundamental","pubTime":"2025-01-10 13:31","pubTimestamp":1736487114,"startTime":"0","endTime":"0","summary":"1月10日，宜明昂科-B(01541)盘中下跌5.42%，截至13:31，报4.89元/股，成交1873.98万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2024年中报，宜明昂科-B营业总收入7.7万元、净利润-1.66亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/10133147329684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2502869492","title":"宜明昂科-B盤中異動 下午盤急速跳水5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502869492","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502869492?lang=zh_tw&edition=fundamental","pubTime":"2025-01-10 13:31","pubTimestamp":1736487112,"startTime":"0","endTime":"0","summary":"2025年01月10日下午盘13时31分，宜明昂科-B股票出现异动，股价大幅下跌5.42%。截至发稿，该股报4.890港元/股，成交量372.34万股，换手率0.97%，振幅7.16%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。宜明昂科-B股票所在的生物技术行业中，整体涨幅为0.08%。宜明昂科-B公司简介：宜明昂科生物医药技术(上海)股份有限公司是一家主要从事测试生物技术研发的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110133153aba56e4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110133153aba56e4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2501790013","title":"港股異動 | 宜明昂科-B(01541)盤中漲超5% 近期出售土地及配股籌集資金 CD47/SIRPα融合蛋白進入III期臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2501790013","media":"智通财经","labels":["shareholding","productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501790013?lang=zh_tw&edition=fundamental","pubTime":"2025-01-08 14:12","pubTimestamp":1736316736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B盘中涨超5%，截至发稿，涨3.19%，报5.18港元，成交额5266.84万港元。此外，宜明昂科近期完成配售事宜，净筹约2.3亿港元，其中70%用于在中国进行包括替达派西普与替雷利珠单抗联合疗法的关键性临床研究提供资金；及约30%作一般企业用途。太平洋证券指出，公司CD47/SIRPα融合蛋白IMM01联合替雷利珠单抗治疗R/R cHL、以及IMM01联合阿扎胞苷治疗1L CMML的III期临床正在积极入组中，有望验证CD47/SIRPα靶点成药性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4134","01541","BK1161"],"gpt_icon":0},{"id":"2501793481","title":"宜明昂科-B盤中異動 大幅上漲5.18%報5.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501793481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501793481?lang=zh_tw&edition=fundamental","pubTime":"2025-01-08 11:32","pubTimestamp":1736307124,"startTime":"0","endTime":"0","summary":"2025年01月08日临近午盘11时32分，宜明昂科-B股票出现波动，股价快速拉升5.18%。截至发稿，该股报5.280港元/股，成交量423.86万股，换手率1.11%，振幅10.16%。资金方面，该股资金流入750.723万港元，流出591.351万港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为1.18%。其相关个股中，瑞科生物-B、腾盛博药-B、宜明昂科-B涨幅较大，振幅较大的相关个股有云顶新耀-B、同源康医药-B、来凯医药-B，振幅分别为13.53%、11.02%、10.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108113204985ebd7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108113204985ebd7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2501424727","title":"宜明昂科-B(01541)上漲5.07%，報5.39元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2501424727","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501424727?lang=zh_tw&edition=fundamental","pubTime":"2025-01-06 09:48","pubTimestamp":1736128139,"startTime":"0","endTime":"0","summary":"1月6日，宜明昂科-B(01541)盘中上涨5.07%，截至09:48，报5.39元/股，成交1439.85万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2024年中报，宜明昂科-B营业总收入7.7万元、净利润-1.66亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/06094847140038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01541","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01541\",params:#limit:5,,,undefined,":[{"date":"2025-03-25","symbol":"01541","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742866200000,"name":null,"time":"盤後","dateTimestamp":1742832000000,"actualEps":null},{"market":"HK","date":"2024-08-26","symbol":"01541","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1724601600000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01541\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01541\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1697558400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01541\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01541","date":"2025-05-13","current":-7.59895,"percent":0.618357,"low":-30.003263,"twenty":-24.82215,"median":-12.331836,"eighty":-5.73806,"high":-2.993766,"avg":-13.632005,"sd":8.265791,"marketCap":2598623094},"quantilePoints":[{"date":"2023-08-31","current":-17.746094,"twenty":-17.746094,"median":-17.746094,"eighty":-17.746094,"marketCap":6942262047},{"date":"2023-09-08","current":-19.116691,"twenty":-19.083294,"median":-18.655615,"eighty":-17.801139,"marketCap":7390149921},{"date":"2023-09-15","current":-24.765877,"twenty":-24.765877,"median":-19.116691,"eighty":-18.557812,"marketCap":9648251285},{"date":"2023-09-22","current":-25.548224,"twenty":-25.200205,"median":-24.360534,"eighty":-18.753419,"marketCap":9909519212},{"date":"2023-09-29","current":-29.804324,"twenty":-26.447668,"median":-24.870232,"eighty":-19.083294,"marketCap":11580180660},{"date":"2023-10-06","current":-24.76052,"twenty":-26.458287,"median":-24.870232,"eighty":-19.110012,"marketCap":9615852761},{"date":"2023-10-13","current":-27.113287,"twenty":-26.458287,"median":-25.206314,"eighty":-22.322253,"marketCap":10513831229},{"date":"2023-10-20","current":-26.768577,"twenty":-26.795293,"median":-25.37532,"eighty":-23.788881,"marketCap":10364168151},{"date":"2023-10-27","current":-28.665306,"twenty":-27.124745,"median":-25.753577,"eighty":-24.00727,"marketCap":11093775656},{"date":"2023-11-03","current":-26.275244,"twenty":-27.500238,"median":-26.158488,"eighty":-24.473108,"marketCap":10195797188},{"date":"2023-11-10","current":-26.039628,"twenty":-27.37617,"median":-26.041732,"eighty":-24.763734,"marketCap":10102257765},{"date":"2023-11-17","current":-26.714897,"twenty":-27.225983,"median":-26.171076,"eighty":-24.792429,"marketCap":10457707575},{"date":"2023-11-24","current":-27.539565,"twenty":-27.37617,"median":-26.271304,"eighty":-24.846191,"marketCap":10869281039},{"date":"2023-12-01","current":-28.464343,"twenty":-27.564693,"median":-26.306056,"eighty":-24.874164,"marketCap":11280854504},{"date":"2023-12-08","current":-27.67933,"twenty":-27.70336,"median":-26.447668,"eighty":-25.070837,"marketCap":10925404694},{"date":"2023-12-15","current":-27.708906,"twenty":-27.817253,"median":-26.526325,"eighty":-25.207536,"marketCap":11000236233},{"date":"2023-12-22","current":-27.916049,"twenty":-27.937914,"median":-26.714897,"eighty":-25.244891,"marketCap":11075067772},{"date":"2023-12-29","current":-28.049426,"twenty":-27.986303,"median":-26.835368,"eighty":-25.288293,"marketCap":11187315080},{"date":"2024-01-05","current":-23.146888,"twenty":-27.970711,"median":-26.68937,"eighty":-25.200205,"marketCap":9166863527},{"date":"2024-01-12","current":-26.439512,"twenty":-27.935571,"median":-26.500765,"eighty":-25.200205,"marketCap":10476415460},{"date":"2024-01-19","current":-25.435754,"twenty":-27.916049,"median":-26.490281,"eighty":-25.212424,"marketCap":10064841995},{"date":"2024-01-26","current":-23.636611,"twenty":-27.83997,"median":-26.442842,"eighty":-24.972615,"marketCap":9316526605},{"date":"2024-02-02","current":-21.195554,"twenty":-27.817533,"median":-26.372788,"eighty":-24.783518,"marketCap":8343716598},{"date":"2024-02-09","current":-18.727145,"twenty":-27.802108,"median":-26.275244,"eighty":-24.041989,"marketCap":7408322361},{"date":"2024-02-16","current":-17.739662,"twenty":-27.801452,"median":-26.252628,"eighty":-23.794995,"marketCap":7019198358},{"date":"2024-02-23","current":-22.387155,"twenty":-27.764049,"median":-26.165159,"eighty":-23.13759,"marketCap":8811413717},{"date":"2024-03-01","current":-17.708555,"twenty":-27.735275,"median":-26.04068,"eighty":-22.460898,"marketCap":6974299434},{"date":"2024-03-08","current":-19.229551,"twenty":-27.718352,"median":-26.025076,"eighty":-21.141323,"marketCap":7576693323},{"date":"2024-03-15","current":-16.157629,"twenty":-27.69116,"median":-25.695795,"eighty":-19.998834,"marketCap":6360680815},{"date":"2024-03-22","current":-15.411367,"twenty":-27.66021,"median":-25.548224,"eighty":-19.057216,"marketCap":6061354659},{"date":"2024-03-28","current":-14.696214,"twenty":-27.629432,"median":-25.408294,"eighty":-18.737655,"marketCap":6038905197},{"date":"2024-04-05","current":-13.011166,"twenty":-27.602384,"median":-25.364375,"eighty":-18.557812,"marketCap":5342971884},{"date":"2024-04-12","current":-13.094845,"twenty":-27.539565,"median":-25.225009,"eighty":-18.239836,"marketCap":5380387654},{"date":"2024-04-19","current":-13.014894,"twenty":-27.51439,"median":-25.154554,"eighty":-17.708555,"marketCap":5342971884},{"date":"2024-04-26","current":-13.779237,"twenty":-27.443648,"median":-24.972615,"eighty":-16.602696,"marketCap":5649781194},{"date":"2024-05-03","current":-12.839078,"twenty":-27.434442,"median":-24.870232,"eighty":-16.184677,"marketCap":5260657191},{"date":"2024-05-10","current":-13.282389,"twenty":-27.357513,"median":-24.774698,"eighty":-14.702373,"marketCap":5455219193},{"date":"2024-05-17","current":-13.228926,"twenty":-27.225983,"median":-24.581805,"eighty":-14.243189,"marketCap":5425286577},{"date":"2024-05-24","current":-13.350651,"twenty":-27.145452,"median":-23.955191,"eighty":-13.966896,"marketCap":5462702347},{"date":"2024-05-31","current":-13.410156,"twenty":-27.124745,"median":-23.750163,"eighty":-13.747349,"marketCap":5492634962},{"date":"2024-06-07","current":-14.158514,"twenty":-27.039336,"median":-23.288627,"eighty":-13.645876,"marketCap":5791961118},{"date":"2024-06-14","current":-13.347574,"twenty":-26.971042,"median":-23.123643,"eighty":-13.527845,"marketCap":5455219193},{"date":"2024-06-21","current":-13.283836,"twenty":-26.926395,"median":-22.448608,"eighty":-13.452996,"marketCap":5417803423},{"date":"2024-06-28","current":-12.683619,"twenty":-26.848726,"median":-21.974147,"eighty":-13.40419,"marketCap":5170859344},{"date":"2024-07-05","current":-11.291057,"twenty":-26.759122,"median":-21.059976,"eighty":-13.359292,"marketCap":4602139648},{"date":"2024-07-12","current":-12.246119,"twenty":-26.720023,"median":-20.206581,"eighty":-13.323498,"marketCap":4998746805},{"date":"2024-07-19","current":-11.915911,"twenty":-26.704686,"median":-19.229551,"eighty":-13.282563,"marketCap":4864050035},{"date":"2024-07-26","current":-11.780484,"twenty":-26.652155,"median":-19.050696,"eighty":-13.224977,"marketCap":4826634265},{"date":"2024-08-02","current":-13.633124,"twenty":-26.594701,"median":-18.753419,"eighty":-13.20236,"marketCap":5582432809},{"date":"2024-08-09","current":-9.567144,"twenty":-26.54166,"median":-18.630761,"eighty":-13.102374,"marketCap":3943622105},{"date":"2024-08-16","current":-8.483685,"twenty":-26.496571,"median":-18.451463,"eighty":-13.086665,"marketCap":3498374448},{"date":"2024-08-23","current":-8.095604,"twenty":-26.47337,"median":-18.020488,"eighty":-13.035717,"marketCap":3352452947},{"date":"2024-08-30","current":-7.377309,"twenty":-26.446703,"median":-17.739662,"eighty":-12.990136,"marketCap":3034418906},{"date":"2024-09-06","current":-4.227864,"twenty":-26.442176,"median":-17.681919,"eighty":-12.840212,"marketCap":1739833281},{"date":"2024-09-13","current":-4.503325,"twenty":-26.43833,"median":-16.602696,"eighty":-12.741292,"marketCap":1848339013},{"date":"2024-09-20","current":-4.539912,"twenty":-26.433601,"median":-16.202037,"eighty":-12.246119,"marketCap":1874530051},{"date":"2024-09-27","current":-5.476578,"twenty":-26.311976,"median":-15.844451,"eighty":-11.915911,"marketCap":2274878785},{"date":"2024-10-04","current":-6.596451,"twenty":-26.302504,"median":-15.05764,"eighty":-11.832338,"marketCap":2727609596},{"date":"2024-10-10","current":-5.983695,"twenty":-26.285201,"median":-14.496802,"eighty":-11.807116,"marketCap":2458216056},{"date":"2024-10-18","current":-5.191078,"twenty":-26.27288,"median":-14.209972,"eighty":-11.719903,"marketCap":2121474130},{"date":"2024-10-25","current":-7.104995,"twenty":-26.248892,"median":-14.119017,"eighty":-11.287262,"marketCap":2903463713},{"date":"2024-11-01","current":-6.615271,"twenty":-26.199776,"median":-13.881638,"eighty":-9.764235,"marketCap":2705160134},{"date":"2024-11-08","current":-6.847628,"twenty":-26.169892,"median":-13.803075,"eighty":-8.441853,"marketCap":2787474827},{"date":"2024-11-15","current":-7.078843,"twenty":-26.118271,"median":-13.690467,"eighty":-8.248986,"marketCap":2851081635},{"date":"2024-11-22","current":-6.784782,"twenty":-26.059844,"median":-13.633178,"eighty":-7.853303,"marketCap":2731351173},{"date":"2024-11-29","current":-5.682581,"twenty":-26.04047,"median":-13.539989,"eighty":-7.45767,"marketCap":2286103516},{"date":"2024-12-06","current":-5.602773,"twenty":-26.037499,"median":-13.514674,"eighty":-7.358253,"marketCap":2248687746},{"date":"2024-12-13","current":-6.121403,"twenty":-26.029477,"median":-13.45004,"eighty":-7.218028,"marketCap":2451992323},{"date":"2024-12-20","current":-5.137492,"twenty":-25.962318,"median":-13.411134,"eighty":-7.087735,"marketCap":2048757705},{"date":"2024-12-27","current":-4.957491,"twenty":-25.887099,"median":-13.400213,"eighty":-7.078006,"marketCap":1975442320},{"date":"2025-01-03","current":-5.238569,"twenty":-25.753577,"median":-13.368079,"eighty":-6.925822,"marketCap":2089488475},{"date":"2025-01-10","current":-5.002231,"twenty":-25.638014,"median":-13.3526,"eighty":-6.765934,"marketCap":1987661551},{"date":"2025-01-17","current":-5.018682,"twenty":-25.5579,"median":-13.317479,"eighty":-6.665777,"marketCap":1995807705},{"date":"2025-01-24","current":-5.323319,"twenty":-25.548224,"median":-13.283546,"eighty":-6.596451,"marketCap":2130219244},{"date":"2025-01-28","current":-5.224689,"twenty":-25.503236,"median":-13.282823,"eighty":-6.532117,"marketCap":2101707706},{"date":"2025-02-07","current":-5.549725,"twenty":-25.42477,"median":-13.246663,"eighty":-6.254752,"marketCap":2219826937},{"date":"2025-02-14","current":-5.930475,"twenty":-25.395104,"median":-13.220128,"eighty":-6.076947,"marketCap":2366457707},{"date":"2025-02-21","current":-6.375256,"twenty":-25.366564,"median":-13.201126,"eighty":-6.054191,"marketCap":2557892324},{"date":"2025-02-28","current":-5.632443,"twenty":-25.318672,"median":-13.116805,"eighty":-5.974648,"marketCap":2252411553},{"date":"2025-03-07","current":-5.782376,"twenty":-25.249925,"median":-13.099044,"eighty":-5.827424,"marketCap":2321653861},{"date":"2025-03-14","current":-4.421401,"twenty":-25.219975,"median":-13.087912,"eighty":-5.725677,"marketCap":1775861550},{"date":"2025-03-21","current":-4.778207,"twenty":-25.207536,"median":-13.071662,"eighty":-5.66584,"marketCap":1918419243},{"date":"2025-03-28","current":-6.735516,"twenty":-25.163684,"median":-13.026305,"eighty":-5.651503,"marketCap":2276850015},{"date":"2025-04-03","current":-7.956153,"twenty":-25.0977,"median":-13.01303,"eighty":-5.66026,"marketCap":2684157710},{"date":"2025-04-11","current":-6.344288,"twenty":-25.036833,"median":-12.972072,"eighty":-5.68428,"marketCap":2126146167},{"date":"2025-04-17","current":-6.122985,"twenty":-24.972615,"median":-12.844749,"eighty":-5.691075,"marketCap":2056903859},{"date":"2025-04-25","current":-8.576896,"twenty":-24.895951,"median":-12.836736,"eighty":-5.703559,"marketCap":2883738480},{"date":"2025-05-02","current":-7.700417,"twenty":-24.872853,"median":-12.82514,"eighty":-5.710649,"marketCap":2594550017},{"date":"2025-05-09","current":-7.730765,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"marketCap":2623061555},{"date":"2025-05-13","current":-7.59895,"twenty":-24.82215,"median":-12.331836,"eighty":-5.73806,"marketCap":2598623094}],"updateTime":1747205466803}}}